[1]
SUTHERLAND EW, DE DUVE C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. The Journal of biological chemistry. 1948 Sep:175(2):663-74
[PubMed PMID: 18880761]
[2]
Unger RH, Ketterer H, Eisentraut AM. Distribution of immunoassayable glucagon in gastrointestinal tissues. Metabolism: clinical and experimental. 1966 Oct:15(10):865-7
[PubMed PMID: 5923522]
[3]
Lund PK, Goodman RH, Dee PC, Habener JF. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proceedings of the National Academy of Sciences of the United States of America. 1982 Jan:79(2):345-9
[PubMed PMID: 7043459]
[4]
Gunawardene AR,Corfe BM,Staton CA, Classification and functions of enteroendocrine cells of the lower gastrointestinal tract. International journal of experimental pathology. 2011 Aug;
[PubMed PMID: 21518048]
[6]
Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. The Journal of biological chemistry. 1992 Apr 15:267(11):7402-5
[PubMed PMID: 1313797]
[7]
Tian L, Jin T. The incretin hormone GLP-1 and mechanisms underlying its secretion. Journal of diabetes. 2016 Nov:8(6):753-765. doi: 10.1111/1753-0407.12439. Epub 2016 Aug 31
[PubMed PMID: 27287542]
[9]
Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism. 2018 Apr 3:27(4):740-756. doi: 10.1016/j.cmet.2018.03.001. Epub
[PubMed PMID: 29617641]
[10]
Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. The Journal of endocrinology. 2012 Dec:215(3):335-46. doi: 10.1530/JOE-12-0368. Epub 2012 Sep 27
[PubMed PMID: 23019069]
[11]
Holst JJ, Albrechtsen NJW, Gabe MBN, Rosenkilde MM. Oxyntomodulin: Actions and role in diabetes. Peptides. 2018 Feb:100():48-53. doi: 10.1016/j.peptides.2017.09.018. Epub
[PubMed PMID: 29412831]
[12]
Lee S,Lee DY, Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Annals of pediatric endocrinology
[PubMed PMID: 28443255]
[13]
Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European journal of biochemistry. 1993 Jun 15:214(3):829-35
[PubMed PMID: 8100523]
[14]
Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005 Sep:48(9):1882-90
[PubMed PMID: 16025254]
[15]
Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut. 1971 Oct:12(10):773-82
[PubMed PMID: 4941684]
[17]
Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clinical pharmacokinetics. 2012 Jul 1:51(7):411-27. doi: 10.2165/11630900-000000000-00000. Epub
[PubMed PMID: 22568694]
[18]
Jeppesen PB. Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therapeutic advances in gastroenterology. 2012 May:5(3):159-71. doi: 10.1177/1756283X11436318. Epub
[PubMed PMID: 22570676]
Level 3 (low-level) evidence
[19]
Wallis K, Walters JR, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Current opinion in clinical nutrition and metabolic care. 2009 Sep:12(5):526-32. doi: 10.1097/MCO.0b013e32832d23cd. Epub
[PubMed PMID: 19474717]
Level 3 (low-level) evidence